Actively Recruiting
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Led by Dana-Farber Cancer Institute · Updated on 2025-10-29
500
Participants Needed
4
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying lung cancer in adults aged 45 years or younger to better understand its causes, risks, and genetic changes. This study focuses on both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which are rare in this younger population. The goal is to improve screening and treatment options for young lung cancer patients by examining tumor and normal genetic alterations. Participants will provide access to their medical records, answer two short questionnaires, and give blood and/or saliva samples. Optional participation includes providing tumor tissue samples or additional blood or tissue samples in the future. The study expects to enroll about 500 people and will continue until it closes or participants withdraw. During the study, researchers will collect data and specimens to build a repository over five years or until study closure. They will track genetic changes in tumors and germline samples to identify cancer-related alterations. Participants can expect to be involved through medical record reviews, brief surveys, and sample collections, with no treatment or intervention assigned by the study team.
CONDITIONS
Brief Title
Biology of Young Lung Cancer Study: The YOUNG LUNG Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 45 and under at lung cancer diagnosis
- Pathologically confirmed bronchogenic lung carcinoma (NSCLC or SCLC) at any treatment time point
- Provision of written informed consent
- Willingness to undergo no more than two peripheral blood draws in a four week period, with no more than 50 ml blood collected over eight weeks
- Individuals under age 18 eligible if legal guardian or parent provides consent
You will not qualify if you...
- Individuals who decline to sign consent
- Individuals unable to give consent or assent and without a designated healthcare proxy
- Compromise of patient diagnosis or staging if tissue is used for research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) for consent and initial questionnaires
Duration - Up to 8 weeks
Participants provide biological specimens and information for research including blood and/or saliva samples, tumor tissue (optional), and medical record data.
Up to 2 visits for blood draws over 4 weeks; additional sample collections may occur if participants consent
Duration - Up to 5 years or until study closure
Participants remain in the study for ongoing data collection through medical records and questionnaires until study closure or withdrawal.
Periodic questionnaires and medical record reviews; visit frequency varies
Trial Site Locations
Total: 4 locations
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Actively Recruiting
2
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02115
Not Yet Recruiting
3
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115
Not Yet Recruiting
4
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
P
Pasi A Janne, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here